New hope for lung cancer that morphs after treatment
NCT ID NCT07001995
First seen Mar 26, 2026 · Last updated Jun 22, 2026 · Updated 9 times
Summary
This study tests a combination of the drug limertinib plus chemotherapy (etoposide and carboplatin) in 30 people with a specific type of lung cancer. These patients have a gene mutation (EGFR) and their cancer has changed from non-small cell to small cell lung cancer after previous treatment. The goal is to see if the combo can slow cancer growth and shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Yongchang Zhang
Changsha, Hunan, 410013, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
limertinib combined with etoposide and carboplatin
What this could lead to
If this works, it could offer a new treatment option for patients whose lung cancer changes form after standard therapy.
What could go wrong
This is a small, early-phase study with only 30 participants, so results may not apply widely. The combination may cause significant side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.